Novacyt SA (ALNOV) Stock Price & News

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia

About Novacyt SA

CEODavid Allmond

Employees२२८

Founded२००६ जुलाई ३

Headquarters-

SectorHealth Care

Industry-

Websitenovacyt.com

Revenue

Net income

All values in GBP	२०२५ सेप्टेम्बर	२०२५ डिसेम्बर	२०२६ मार्च	२०२६ जुन
Revenue	५१.१८ लाख	५१.१८ लाख	५७.७८ लाख	५७.७८ लाख
Cost of goods sold	२६.१४ लाख	२६.१४ लाख	२५.६० लाख	२५.६० लाख
Cost of revenue	२६.१४ लाख	२६.१४ लाख	२५.६० लाख	२५.६० लाख
Research and development expenses	१०.३४ लाख	१०.३४ लाख	१०.५८ लाख	१०.५८ लाख
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	४६.८८ लाख	४६.८८ लाख	४६.४९ लाख	४६.४९ लाख
Operating expense	५५.४२ लाख	५५.४२ लाख	५६.६३ लाख	५६.६३ लाख
Total operating expenses	८१.५६ लाख	८१.५६ लाख	८२.२२ लाख	८२.२२ लाख
Operating income	-३०.३८ लाख	-३०.३८ लाख	-२४.४४ लाख	-२४.४४ लाख
Other non operating income	-२३.०० हजार	-२३.०० हजार	-४७.५० हजार	-४७.५० हजार
EBT including unusual items	-१.०२ करोड	-१.०२ करोड	-२९.०६ लाख	-२९.०६ लाख
EBT excluding unusual items	-२५.१८ लाख	-२५.१८ लाख	-२७.९८ लाख	-२७.९८ लाख
Income tax expense	-१८.१४ लाख	-१८.१४ लाख	-४९.५० हजार	-४९.५० हजार
Effective tax rate	१७.८५%	१७.८५%	१.७०%	१.७०%
Other operating expenses	-१.८० लाख	-१.८० लाख	-४४.०० हजार	-४४.०० हजार
Net income	-८२.७० लाख	-८२.७० लाख	-२८.९७ लाख	-२८.९७ लाख
Net profit margin	-१६१.६०%	-१६१.६०%	-५०.१३%	-५०.१३%
Earnings per share	-	-	-	-
Interest and investment income	१.४९ लाख	१.४९ लाख	६३.०० हजार	६३.०० हजार
Interest expense	-१.४६ लाख	-१.४६ लाख	-१.३९ लाख	-१.३९ लाख
Net interest expenses	३.०० हजार	३.०० हजार	-७६.०० हजार	-७६.०० हजार
Depreciation and amortization charges	-	-	-	-
EBITDA	३४.६३ लाख	३४.६३ लाख	-१८.८५ लाख	-१८.८५ लाख
Gain or loss from assets sale	-३.०० हजार	-३.०० हजार	८.०० हजार	८.०० हजार

Finance

Ask anything